TaiMed Biologics Inc. (4147.TWO)
TWD 82.5
(-0.48%)
TWD 82.5
(-0.48%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -25.23 Million TWD | 76.05% |
| 2022 | -103.36 Million TWD | 66.51% |
| 2021 | -307.45 Million TWD | -678.08% |
| 2020 | -40.05 Million TWD | 91.88% |
| 2019 | -486.69 Million TWD | -88.37% |
| 2018 | -258.9 Million TWD | 52.37% |
| 2017 | -541.43 Million TWD | -74.99% |
| 2016 | -309.41 Million TWD | 33.92% |
| 2015 | -487.71 Million TWD | -82.87% |
| 2014 | -256.06 Million TWD | -11.86% |
| 2013 | -228.91 Million TWD | -30.04% |
| 2012 | -145.18 Million TWD | -1.91% |
| 2011 | -172.74 Million TWD | 19.62% |
| 2010 | -214.9 Million TWD | -37.64% |
| 2009 | -163.62 Million TWD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 1.55 Million TWD | 247.14% |
| 2024 Q2 | -2.74 Million TWD | -47.5% |
| 2023 Q2 | -5.26 Million TWD | 86.21% |
| 2023 FY | - TWD | 76.05% |
| 2023 Q1 | -38.14 Million TWD | -936.9% |
| 2023 Q4 | -17.8 Million TWD | -148.64% |
| 2023 Q3 | 36.59 Million TWD | 795.63% |
| 2022 Q2 | -34.2 Million TWD | 56.66% |
| 2022 Q1 | -78.93 Million TWD | 69.4% |
| 2022 FY | - TWD | 66.51% |
| 2022 Q4 | 4.55 Million TWD | -21.9% |
| 2022 Q3 | 5.83 Million TWD | 117.06% |
| 2021 Q4 | -257.93 Million TWD | -599.26% |
| 2021 FY | - TWD | -678.08% |
| 2021 Q1 | 46.06 Million TWD | 190.55% |
| 2021 Q2 | -58.07 Million TWD | -226.07% |
| 2021 Q3 | -36.88 Million TWD | 36.48% |
| 2020 Q1 | -46.13 Million TWD | 16.3% |
| 2020 FY | - TWD | 91.88% |
| 2020 Q2 | 65.65 Million TWD | 242.31% |
| 2020 Q3 | -8.08 Million TWD | -112.31% |
| 2020 Q4 | -50.87 Million TWD | -529.51% |
| 2019 Q4 | -55.11 Million TWD | 81.62% |
| 2019 Q1 | -69.1 Million TWD | 31.09% |
| 2019 Q2 | -43.64 Million TWD | 36.85% |
| 2019 FY | - TWD | -88.37% |
| 2019 Q3 | -299.94 Million TWD | -587.27% |
| 2018 Q2 | -308.19 Million TWD | -430.57% |
| 2018 Q4 | -100.27 Million TWD | 23.91% |
| 2018 Q3 | -131.78 Million TWD | 57.24% |
| 2018 Q1 | 93.23 Million TWD | 153.07% |
| 2018 FY | - TWD | 52.37% |
| 2017 Q2 | -191.69 Million TWD | -176.41% |
| 2017 FY | - TWD | -74.99% |
| 2017 Q4 | -175.65 Million TWD | -67.74% |
| 2017 Q1 | -69.35 Million TWD | 39.2% |
| 2017 Q3 | -104.72 Million TWD | 45.37% |
| 2016 FY | - TWD | 33.92% |
| 2016 Q4 | -114.07 Million TWD | -107.38% |
| 2016 Q3 | -55 Million TWD | 28.71% |
| 2016 Q2 | -77.15 Million TWD | -22.12% |
| 2016 Q1 | -63.17 Million TWD | 35.28% |
| 2015 Q1 | -64.68 Million TWD | 1.77% |
| 2015 FY | - TWD | -82.87% |
| 2015 Q4 | -97.61 Million TWD | 47.99% |
| 2015 Q3 | -187.69 Million TWD | -58.71% |
| 2015 Q2 | -118.25 Million TWD | -82.83% |
| 2014 Q2 | -48.98 Million TWD | 24.71% |
| 2014 FY | - TWD | -11.86% |
| 2014 Q1 | -65.05 Million TWD | 23.59% |
| 2014 Q3 | -76.17 Million TWD | -55.5% |
| 2014 Q4 | -65.85 Million TWD | 13.55% |
| 2013 Q1 | -42.79 Million TWD | 25.81% |
| 2013 Q2 | -42.79 Million TWD | 0.0% |
| 2013 Q3 | -85.13 Million TWD | -98.96% |
| 2013 FY | - TWD | -30.04% |
| 2013 Q4 | -85.13 Million TWD | 0.0% |
| 2012 Q2 | - TWD | 0.0% |
| 2012 FY | - TWD | -1.91% |
| 2012 Q3 | -57.67 Million TWD | 0.0% |
| 2012 Q4 | -57.67 Million TWD | 0.0% |
| 2011 FY | - TWD | 19.62% |
| 2011 Q4 | - TWD | 0.0% |
| 2011 Q2 | - TWD | 0.0% |
| 2010 FY | - TWD | -37.64% |
| 2010 Q4 | - TWD | 0.0% |
| 2009 FY | - TWD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bio Preventive Medicine Corp. | -62.34 Million TWD | 59.524% |
| Genomics BioSci & Tech. Co.,Ltd. | -103.61 Million TWD | 75.647% |
| Advagene Biopharma Co., Ltd. | -80.07 Million TWD | 68.487% |
| Taiwan Bio Therapeutics Co., Ltd | -145.97 Million TWD | 82.714% |
| NaviFUS Corp. | -55.79 Million TWD | 54.776% |
| G&E Herbal Biotechnology Co., Ltd. | 99.83 Million TWD | 125.274% |
| TaiRx, Inc. | -208.64 Million TWD | 87.906% |
| Sinew Pharma Inc. | -163.63 Million TWD | 84.579% |
| Lin BioScience, Inc. | -1.07 Billion TWD | 97.645% |
| TaiwanJ Pharmaceuticals Co., Ltd. | -1.73 Million TWD | -1352.677% |
| Lumosa Therapeutics Co., Ltd. | -226.67 Million TWD | 88.868% |
| Anti-Microbial Savior BioteQ Co., Ltd | -46.24 Million TWD | 45.435% |
| SYN-TECH Chem. & Pharm. Co., Ltd. | 393.6 Million TWD | 106.411% |
| AP Biosciences Inc | -325.51 Million TWD | 92.248% |
| Sunmax Biotechnology Co., Ltd. | 936.46 Million TWD | 102.694% |
| RBC Bioscience Corporation | 36.54 Million TWD | 169.043% |
| Syngen Biotech Co.,Ltd. | 433.55 Million TWD | 105.82% |
| EirGenix Inc. | -664.4 Million TWD | 96.202% |
| Enimmune corporation | -228.96 Million TWD | 88.979% |
| Lukas Biomedical Inc. | -26.3 Million TWD | 4.057% |
| BRIM Biotechnology, Inc. | -682.46 Million TWD | 96.303% |
| 3D Global Biotech Inc. | -35.84 Million TWD | 29.607% |
| Mycenax Biotech Inc. | -339.48 Million TWD | 92.567% |
| TCI GENE Inc. | 25.98 Million TWD | 197.121% |
| SynCore Biotechnology Co.,Ltd | -17.72 Million TWD | -42.35% |
| Oneness Biotech Co., Ltd. | -674.22 Million TWD | 96.258% |
| Eusol Biotech Co.,Ltd. | -44.95 Million TWD | 43.866% |
| Feng Chi Biotech Corp. | 34.83 Million TWD | 172.43% |
| NeoCore Technology Co., Ltd. | -72.11 Million TWD | 65.01% |
| TWi Biotechnology, Inc. | -160.85 Million TWD | 84.313% |
| Neith Corporation | -33.61 Million TWD | 24.924% |
| Sunny Pharmtech Inc. | 69.14 Million TWD | 136.494% |
| VBI | -6.97 Million TWD | -261.919% |
| Ever Supreme Bio Technology Co., Ltd | 655.52 Million TWD | 103.849% |
| GeneReach Biotechnology Corp. | -143.69 Million TWD | 82.44% |
| Shine-On BioMedical Co.,Ltd. | -33 Million TWD | 23.55% |
| CHO Pharma, Inc. | -277.73 Million TWD | 90.915% |
| Andros Pharmaceuticals Co.,Ltd | -61.5 Million TWD | 58.971% |
| MegaPro Biomedical Co., Ltd | -110.63 Million TWD | 77.193% |
| Visgeneer Inc. | 973 Thousand TWD | 2693.32% |
| Greenyn Biotechnology Co., Ltd | 192.4 Million TWD | 113.115% |
| BioLASCO Taiwan Co., Ltd. | 73.9 Million TWD | 134.143% |
| Gwo Xi Stem Cell Applied Technology Co. , Ltd | -16.59 Million TWD | -52.024% |
| Sagittarius Life Science Corp | -44.73 Million TWD | 43.6% |
| BioGend Therapeutics Co., Ltd. | -113.1 Million TWD | 77.691% |
| GlycoNex Incorporation | -126.82 Million TWD | 80.104% |
| Medigen Biotechnology Corp. | -1.04 Billion TWD | 97.584% |
| Pharmosa Biopharm Inc. | 29.13 Million TWD | 186.622% |
| PharmaEngine, Inc. | 347.3 Million TWD | 107.265% |
| Intech Biopharm Corporation | -219.58 Million TWD | 88.509% |
| Taiwan Advance Bio-Pharmaceutical Inc. | 21.81 Million TWD | 215.695% |
| BiOptic Inc. | 65.03 Million TWD | 138.797% |
| TaiGen Biopharmaceuticals Holdings Limited | 172.23 Million TWD | 114.651% |
| Senhwa Biosciences, Inc. | -283.78 Million TWD | 91.108% |
| NatureWise Biotech & Medicals Corporation | 13.85 Million TWD | 282.188% |
| OBI Pharma, Inc. | -855.08 Million TWD | 97.049% |
| Savior Lifetec Corporation | 219.6 Million TWD | 111.49% |
| Great Novel Therapeutics Biotech & Medicals | -54.91 Million TWD | 54.051% |
| Level Biotechnology Inc. | 98.7 Million TWD | 125.564% |
| Medigen Vaccine Biologics Corporation | -991.09 Million TWD | 97.454% |
| Meribank Biotech Co., Ltd | -92.56 Million TWD | 72.74% |
| Acepodia, Inc. | -764.51 Million TWD | 96.699% |
| Caliway Biopharmaceuticals Co., Ltd. | -460.09 Million TWD | 94.516% |